Ask for Details About Our New Lyo-Consultancy Packages!

Avestin Emulsiflex: Supporting the frontiers of Cancer research

by biopharma-admin in Uncategorized

 

Case Study

Avestin Emulsiflex: Supporting the frontiers of Cancer research

Use of Avestin Liposome Extrusion.

 

Background

Bacteria can cause many different types of infections as they have many virulence factors for example adherence proteins, capsules, biofilm formation, endotoxins and exotoxins. Bacterial infections can be mild or severe but can be treated with narrow or broad-spectrum antibiotics. Antibiotic therapy is a selective pressure for the evolution antibiotic resistant bacterial strain, which can make therapy very difficult. In the UK this is of major concern as these bacteria are considered to be a ‘perilous threat’. One of the least studied virulent mechanisms is PFTs (exotoxins). PFTs are proteins released by bacteria that are widely distributed and form lesions in the host cellular membrane. ​These PFTs can cause severe sepsis and septic shock in patients.

 

Application

At the school of biomedical science at University of Central Lancashire they are involved in developing nano-sponges, which is a nano-particle that will clean these pore forming toxins from the human body. Thus for the creation and development of these nano-sponges the Avestin range will be playing a key role due to the ability to generate a low particle size, pre-set vesicle size and the homogeneity in the respective size distribution.

Looking at the larger picture, these nano-sponges will be utilised as a drug delivery system to deliver drugs to patients suffering from glioblastoma, the most aggressive malignant primary brain tumour in humans, involving glial cells and accounting for 52% of all functional tissue brain tumour cases and 20% of all intracranial tumours.

The Avestin Emulsiflex system currently supports significant research into these brain tumours at the University of Central Lancashire in the areas demonstrated below. Moreover the findings of this research is also shared with Brain Tumour North West, a strategic amalgamation of UCLan, the Neurosurgical Unit and Neuropathology Department at the Royal Preston hospital and others across the North West.

 

  • Drug design, analysis and delivery
  • The role of dietary supplements as treatments forglioblastoma
  • Therapeutic potential of asiatic acid inglioblastoma treatment, focusing on novel drug delivery methods
  • Neuronal and tissue dysfunction
  • Preliminary biological evaluation and mechanism of action studies of selected 2- arylindoles againstglioblastoma
  • Aptamers to determine their use in the diagnosis and treatment ofGlioblastoma

 

UCLan Glioblasphoma images x 3 V2